{
    "SPADE_UN_24472": {
        "Sequence Information": {
            "Peptide Name": "ACE2 (20-49)[6-R-ALA-7-oct; 13,24,28-S-ALA-4-pen]",
            "Sequence": "TIEEQXKTFLDKXNHEAEDLFYQXSLAXWN",
            "Sequence Length": 30,
            "Biological Activity": [
                "Antiviral",
                "Anticancer"
            ],
            "Binding Target": "1. Virus entry",
            "Source": "",
            "Gene": "",
            "PDB ID": "",
            "UniProt Entry": [
                {
                    "uniprotId": "Q9BYF1",
                    "uniprotUrl": "http://www.uniprot.org/uniprot/Q9BYF1",
                    "description": "The amino acid sequence of the current peptide coincides with the part of the UniProt entry that may represent a peptide precursor."
                }
            ],
            "Literature": [
                {
                    "Title": "Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro.",
                    "Pubmed ID": "33310780",
                    "Reference": "MBio. 2020;11:e02451-20",
                    "Author": "Curreli F, Victor SMB, Ahmed S, Drelich A, Tong X, Tseng CK, Hillyer CD, Debnath AK",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/33310780"
                }
            ],
            "SPADE ID": "SPADE_UN_24472",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_13534",
                    "Similarity": 1.0,
                    "Sequence": "TFLDKFNHEAEDLFYQ"
                },
                {
                    "SPADE_ID": "SPADE_UN_13874",
                    "Similarity": 1.0,
                    "Sequence": "NHEAEDLFY"
                },
                {
                    "SPADE_ID": "SPADE_UN_13539",
                    "Similarity": 1.0,
                    "Sequence": "EDLFYQ"
                }
            ],
            "Hemolytic Activity": "",
            "Target Organism": "SARS-CoV-2 PsV(IC50 I=1.97±0.14µM),SARS-CoV-2 PsV(IC50 I=2.8±0.08µM),Vesicular Stomatitis Virus (VSV) PsV(IC50 I=>26.6µM),Human lung carcinoma A549(50-60% Cytotoxicity=>26.6µM),Human fibrosarcoma HT1080(50-60% Cytotoxicity=>26.6µM),SARS-CoV-2(90-100% Inhibition=33µM)"
        }
    }
}